TECVAYLI and DARZALEX FASPRO Show Strong Myeloma Response
September 19, 2025
Johnson & Johnson shared encouraging results from an investigational treatment that combines TECVAYLI with DARZALEX FASPRO in patients newly diagnosed with multiple myeloma who are